For the IDH mutant pHGG subgroup, blood–brain barrier penetrant IDH inhibitors have been developed for glioma trials (NCT02273739, NCT03343197, NCT02073994 and NCT04056910). This evidence concerns the gene IDH2 and central nervous system cancer.